MCID: INS002
MIFTS: 55

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 44 72

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
MeSH 44 D002278
NCIt 50 C2917
SNOMED-CT 68 68956006
ICD10 33 D09.9
UMLS 72 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and endometrium carcinoma in situ. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Circadian entrainment and Endometrial cancer. The drugs Aluminum hydroxide and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and lymph node, and related phenotypes are cellular and growth/size/body region

Wikipedia : 75 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the in Situ Carcinoma family:

Pre-Malignant Neoplasm Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 631)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 34.0 ESR1 ERBB2
2 endometrium carcinoma in situ 34.0 TP53 PGR
3 cervix uteri carcinoma in situ 33.4 TP53 KRT17 CDKN2A
4 breast carcinoma in situ 32.2 TP53 PGR KRT5 ESR1 ERBB2 EGFR
5 uterus carcinoma in situ 32.1 TP53 KRT17 CDKN2A
6 vulva cancer 30.8 TP53 EGFR CDKN2A
7 tubular adenocarcinoma 30.8 PGR ESR1 ERBB2 CDH1
8 cervical squamous cell carcinoma 30.7 TP53 CDKN2A CDH1
9 carcinosarcoma 30.6 TP53 PGR ERBB2
10 actinic keratosis 30.6 TP53 KRT17 CDKN2A
11 small cell carcinoma 30.5 TP53 EGFR CDKN2A
12 endometrial squamous cell carcinoma 30.5 PGR ESR1 CDKN2A
13 cystadenocarcinoma 30.5 TP53 PGR ERBB2
14 apocrine adenocarcinoma 30.4 PGR KRT5 ESR1 ERBB2
15 bilateral breast cancer 30.4 PGR ERBB2 BRCA1
16 lobular neoplasia 30.4 ESR1 ERBB2 CDH1 BRCA1
17 cholecystitis 30.3 TP53 CDKN2A CDH1
18 intrahepatic cholangiocarcinoma 30.3 TP53 EGFR CDH1
19 serous cystadenocarcinoma 30.3 TP53 PGR ERBB2
20 adenosquamous carcinoma 30.2 TP53 KRT5 EGFR
21 papillary serous adenocarcinoma 30.2 TP53 PGR BRCA1
22 female breast cancer 30.2 TP53 PGR ESR1 ERBB2 BRCA1
23 mammary paget's disease 30.1 PGR ESR1 ERBB2 EGFR
24 breast fibroadenoma 30.0 PGR KRT14 ESR1 ERBB2
25 vulva squamous cell carcinoma 30.0 TP53 KRT17 CDKN2A
26 microglandular adenosis 30.0 TP53 PGR ERBB2 EGFR
27 spindle cell carcinoma 30.0 PGR KRT5 KRT14 CDH1
28 papillary carcinoma 29.9 PGR ERBB2 CDH1
29 bladder disease 29.9 TP53 ERBB2 CDKN2A CDH1
30 breast adenocarcinoma 29.9 TP53 ESR1 ERBB2 EGFR
31 pleomorphic adenoma 29.9 TP53 KRT14 ERBB2
32 wilms tumor 1 29.9 TP53 PGR ESR1 ERBB2
33 papilloma 29.9 TP53 KRT5 KRT14 CDKN2A
34 penile cancer 29.8 TP53 EGFR CDKN2A
35 cervical adenocarcinoma 29.6 TP53 PGR ESR1 ERBB2 CDKN2A
36 cholangiocarcinoma 29.6 TP53 ERBB2 EGFR CDKN2A CDH1
37 fallopian tube carcinoma 29.6 TP53 PGR ESR1 ERBB2 BRCA1
38 sporadic breast cancer 29.6 TP53 PGR ESR1 ERBB2 BRCA1
39 skin disease 29.5 KRT5 KRT17 KRT14 ITGB4
40 oral cancer 29.5 TP53 EGFR CDKN2A CDH1
41 pleomorphic adenoma carcinoma 29.4 TP53 ERBB2
42 breast disease 29.4 TP53 PGR KRT5 ESR1 ERBB2 BRCA1
43 lynch syndrome 29.3 TP53 EGFR CDKN2A BRCA1
44 transitional cell carcinoma 29.3 TP53 ERBB2 EGFR CDKN2A CDH1
45 bladder cancer 29.3 TP53 ERBB2 EGFR CDKN2A CDH1
46 ovarian cancer 29.1 TP53 PGR ESR1 ERBB2 EGFR CDH1
47 adenocarcinoma 29.1 TP53 ERBB2 EGFR CDKN2A CDH1
48 gallbladder cancer 29.1 TP53 ERBB2 EGFR CDKN2A CDH1
49 breast squamous cell carcinoma 29.0 TP53 KRT5 KRT14 ERBB2 EGFR
50 endometrial adenocarcinoma 29.0 TP53 PGR ESR1 ERBB2 EGFR CDKN2A

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
2 growth/size/body region MP:0005378 10.45 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
3 homeostasis/metabolism MP:0005376 10.45 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
4 cardiovascular system MP:0005385 10.44 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
5 digestive/alimentary MP:0005381 10.42 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
6 mortality/aging MP:0010768 10.41 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
7 immune system MP:0005387 10.39 AGTR1 BRCA1 CDH1 CDKN2A EGFR ESR1
8 behavior/neurological MP:0005386 10.38 AGTR1 BRCA1 CDKN2A ERBB2 ESR1 ITGB4
9 endocrine/exocrine gland MP:0005379 10.37 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
10 integument MP:0010771 10.37 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
11 hematopoietic system MP:0005397 10.35 AGTR1 BRCA1 CDKN2A EGFR ESR1 KRT14
12 embryo MP:0005380 10.27 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
13 adipose tissue MP:0005375 10.16 AGTR1 BRCA1 EGFR ESR1 KRT14 NR3C1
14 craniofacial MP:0005382 10.13 EGFR ERBB2 ITGB4 KRT14 KRT17 KRT5
15 muscle MP:0005369 10.09 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
16 neoplasm MP:0002006 10.06 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
17 limbs/digits/tail MP:0005371 10.02 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
18 no phenotypic analysis MP:0003012 10.02 CDH1 CDKN2A EGFR ESR1 KRT17 KRT5
19 renal/urinary system MP:0005367 9.91 AGTR1 BRCA1 EGFR ESR1 FKBP4 ITGB4
20 reproductive system MP:0005389 9.9 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
21 pigmentation MP:0001186 9.8 BRCA1 CDKN2A EGFR KRT14 KRT17 TP53
22 respiratory system MP:0005388 9.65 BRCA1 CDKN2A EGFR ERBB2 ESR1 ITGB4
23 skeleton MP:0005390 9.28 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6
BCG vaccine Investigational Phase 4
7 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
8 Hypolipidemic Agents Phase 4
9 Lipid Regulating Agents Phase 4
10 Anticholesteremic Agents Phase 4
11 Monophosphoryl lipid A Phase 4
12 Autonomic Agents Phase 4
13 Vasoconstrictor Agents Phase 4
14 Interferon alpha-2 Phase 4
15 Interferon-alpha Phase 4
16 Sympathomimetics Phase 4
17 Anesthetics, Local Phase 4
18 Adrenergic Agonists Phase 4
19 Respiratory System Agents Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Adrenergic beta-Agonists Phase 4
22 Epinephryl borate Phase 4
23 Mydriatics Phase 4
24 Adrenergic Agents Phase 4
25 Anti-Asthmatic Agents Phase 4
26 Bronchodilator Agents Phase 4
27 Vaccines Phase 4
28 Immunologic Factors Phase 4
29 Alkylating Agents Phase 4
30 Adjuvants, Immunologic Phase 4
31 Mitomycins Phase 4
32 Nucleic Acid Synthesis Inhibitors Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Anti-Bacterial Agents Phase 4
35
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
38
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
39
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
40
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
41
leucovorin Approved Phase 3 58-05-9 143 6006
42
Pembrolizumab Approved Phase 3 1374853-91-4
43
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
44
acetic acid Approved Phase 3 64-19-7 176
45
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
46
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
47
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
48
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
49
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
50
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 681)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast Completed NCT01448447 Phase 4
5 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
6 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
7 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
8 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
9 Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
10 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
11 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
12 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
13 HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial Recruiting NCT03051516 Phase 4
14 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
15 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
16 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
17 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
18 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
19 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
20 Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks. Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
21 A Randomized Prospective Open Multicentric Phase III Clinical Trial Compared TC, FEC100 Followed by Docetaxel and EC90 Followed by Paclitaxel as Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients Unknown status NCT01314833 Phase 3 Docetaxel Cyclophosphamide;Cyclophosphamide Fluorouracil Epirubicin Docetaxel;Epirubicin Cyclophosphamide Paclitaxel
22 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
23 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
24 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
25 SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS Unknown status NCT00629278 Phase 3 aromatase inhibition therapy;cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;paclitaxel;releasing hormone agonist therapy;tamoxifen citrate
26 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
27 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
28 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
29 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
30 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
31 An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
32 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
33 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
34 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
35 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
36 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
37 A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
38 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
39 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
40 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
41 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
42 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
43 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
44 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
45 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
46 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
47 Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group) Completed NCT02295033 Phase 3
48 A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer Completed NCT00233402 Phase 3 Hexvix
49 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
50 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

41
Breast, Cervix, Lymph Node, Lung, Testes, Testis, Skin

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 16900)
# Title Authors PMID Year
1
Feasibility of transnasal flexible carbon dioxide laser surgery for laryngopharyngeal lesions. 38
30765273 2019
2
Diffusional kurtosis imaging for differentiation of additional suspicious lesions on preoperative breast MRI of patients with known breast cancer. 38
31323316 2019
3
Sentinel node mapping and ductal carcinoma in situ. 38
30903404 2019
4
Variability in the Management Recommendations Given for High-risk Breast Lesions Detected on Image-guided Core Needle Biopsy at U.S. Academic Institutions. 38
30075881 2019
5
Mixed Adenocarcinomatous and Neuroendocrine Tumor of the Urinary Bladder With Concomitant Carcinoma In Situ: A Case Report With a Comprehensive Immunohistochemical Analysis and Review of the Literature. 38
30955388 2019
6
The effect of treatment on patient-reported distress after breast cancer diagnosis. 38
31120575 2019
7
Severe acne and risk of breast cancer. 38
31165375 2019
8
The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions. 38
31028940 2019
9
MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. 38
30259272 2019
10
Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. 38
30993692 2019
11
Quality of DCIS information on the internet: a content analysis. 38
31214858 2019
12
Airborne mammary carcinogens and breast cancer risk in the Sister Study. 38
31226564 2019
13
Urothelial Carcinoma In Situ (CIS): New Insights. 38
31149909 2019
14
Imaging features that distinguish pure ductal carcinoma in situ (DCIS) from DCIS with microinvasion. 38
31396390 2019
15
Getting on the Nerves: A Case of Perineural Invasion by Mammary Ductal Carcinoma In Situ. 38
30482072 2019
16
Ductal Carcinoma In Situ of the Breast: Controversies and Current Management. 38
31327448 2019
17
Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification. 38
31192864 2019
18
Is Sentinel Lymph Node Biopsy Required for a Core Biopsy Diagnosis of Ductal Carcinoma In Situ with Microinvasion? 38
31147995 2019
19
Breast-Conserving Surgery in Patients With Mammary Paget's Disease. 38
31026796 2019
20
Oncologic outcomes and radiation safety of nipple-sparing mastectomy with intraoperative radiotherapy for breast cancer. 38
30888580 2019
21
Changes in mammographic density over time and the risk of breast cancer: An observational cohort study. 38
31132476 2019
22
Clear Cell Endometrial Carcinoma In Situ (CCEIC) Exists! 38
31416376 2019
23
Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. 38
31391072 2019
24
Interobserver variability and likelihood of malignancy for fifth edition BI-RADS MRI descriptors in non-mass breast lesions. 38
31392476 2019
25
Assessment of Machine Learning of Breast Pathology Structures for Automated Differentiation of Breast Cancer and High-Risk Proliferative Lesions. 38
31397859 2019
26
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. 38
31221620 2019
27
[Organ preservation by chemoradiation for bladder cancer]. 38
31400955 2019
28
Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. 38
30986485 2019
29
Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer. 38
31366524 2019
30
[Sebaceous carcinoma in situ in extraocular skin : Case report and discussion of the new entity]. 38
31420711 2019
31
Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy. 38
31227894 2019
32
Contrast-enhanced MRI for breast cancer screening. 38
30659696 2019
33
Prognostic role of immune infiltrates in breast ductal carcinoma in situ. 38
31134489 2019
34
BI-RADS Category 5 Assessments at Diagnostic Breast Imaging:Outcomes Analysis Based on Lesion Descriptors. 38
30195413 2019
35
Syphilitic Cervicitis with Cervical Cancer Presenting as Oropharyngeal Syphilis. 38
30996173 2019
36
Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? 38
31375867 2019
37
International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. 38
31431385 2019
38
Letter regarding Sopik V et al. entitled "Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ". 38
31432364 2019
39
Surgery and adjuvant radiotherapy for unilateral ductal carcinoma in situ (DCIS) in women aged over 70 years: A population based cohort study. 38
30878169 2019
40
Accuracy of tumor size measurements performed by magnetic resonance, ultrasound and mammography, and their correlation with pathological size in primary breast cancer. 38
31186117 2019
41
Preoperative breast MRI features associated with positive or close margins in breast-conserving surgery. 38
31307644 2019
42
Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. 38
31247278 2019
43
Value of Shear Wave Elastography for the Differentiation of Benign and Malignant Microcalcifications of the Breast. 38
31039014 2019
44
A Single-Session Acceptance and Commitment Therapy Intervention among Women Undergoing Surgery for Breast Cancer: A Randomized Pilot Trial to Reduce Persistent Postsurgical Pain. 38
31430830 2019
45
Oncoplastic Level 2 Mammoplasty for Large DCIS: 5-Year Results. 38
31087179 2019
46
MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. 38
31400007 2019
47
The impact of an online patient decision aid for women with breast cancer considering immediate breast reconstruction: study protocol of a multicenter randomized controlled trial. 38
31426772 2019
48
Circumferential Shaving of the Cavity in Breast-Conserving Surgery: A Randomized Controlled Trial. 38
31429019 2019
49
An audit of mammographic screen detected lesions of uncertain malignant potential (B3) diagnosed on initial image guided needle biopsy: how has our practice changed over 10 years? 38
31078275 2019
50
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. 38
31054033 2019

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 PPP3R1 PGR KRT17 KRT14 FKBP4 ESR1
2
Show member pathways
12.78 TP53 ERBB2 EGFR CDKN2A CDH1
3 12.64 TP53 ESR1 ERBB2 EGFR CDKN2A CDH1
4
Show member pathways
12.46 TP53 ESR1 ERBB2 EGFR CDKN2A CDH1
5 12.4 TP53 ERBB2 EGFR CDKN2A BRCA1
6
Show member pathways
12.22 TP53 PGR ESR1 ERBB2 EGFR CDKN2A
7 12.18 TP53 ESR1 ERBB2 EGFR
8
Show member pathways
12.14 PPP3R1 ERBB2 EGFR AGTR1
9
Show member pathways
12.1 TP53 ITGB4 ERBB2 EGFR
10
Show member pathways
12.08 PGR NR3C1 ESR1 CDKN2A BRCA1
11 11.99 TP53 ITGB4 ERBB2 EGFR
12 11.99 TP53 ESR1 EGFR CDH1 BRCA1
13
Show member pathways
11.83 PGR ESR1 ERBB2 EGFR
14
Show member pathways
11.77 ESR1 ERBB2 EGFR
15 11.76 FKBP4 EGFR BRCA1
16
Show member pathways
11.75 PGR NR3C1 ESR1
17 11.63 ERBB2 EGFR CDH1
18 11.62 TP53 ERBB2 CDKN2A BRCA1
19 11.59 TP53 ERBB2 EGFR
20 11.58 TP53 ERBB2 BRCA1
21 11.52 ITGB4 ERBB2 BRCA1
22 11.42 TP53 ERBB2 EGFR CDKN2A CDH1
23 11.41 TP53 EGFR CDKN2A
24 11.29 PPP3R1 ITGB4 ERBB2 EGFR
25 11.05 ITGB4 ERBB2 EGFR CDH1
26 11.01 TP53 NR3C1 KRT5 KRT17 KRT14 FKBP4
27 10.59 NR3C1 FKBP4

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.55 TP53 PRDX2 PPP3R1 PPIA PGR PDPN
2 protein-containing complex GO:0032991 9.5 TP53 PPIA NR3C1 FKBP4 ESR1 EGFR
3 cytosol GO:0005829 10 TP53 PRDX2 PPP3R1 PPIA PGR PDPN

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.83 TP53 PRDX2 ESR1 BRCA1
2 positive regulation of transcription, DNA-templated GO:0045893 9.73 TP53 ESR1 EGFR CDKN2A CDH1 BRCA1
3 positive regulation of cell growth GO:0030307 9.65 KRT17 ERBB2 EGFR
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 TP53 PPP3R1 PGR NR3C1 ESR1 EGFR
5 replicative senescence GO:0090399 9.51 TP53 CDKN2A
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 TP53 BRCA1
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.46 TP53 ESR1
8 epidermis development GO:0008544 9.46 KRT5 KRT17 KRT14 EGFR
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
10 negative regulation of ERBB signaling pathway GO:1901185 9.4 ERBB2 EGFR
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.37 ERBB2 CDKN2A
12 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 BRCA1
13 hemidesmosome assembly GO:0031581 8.8 KRT5 KRT14 ITGB4

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 TP53 PGR ESR1 ERBB2 EGFR CDH1
2 protein kinase binding GO:0019901 9.8 TP53 NR3C1 ESR1 EGFR CDKN2A
3 enzyme binding GO:0019899 9.65 TP53 PGR ESR1 EGFR BRCA1
4 protein phosphatase binding GO:0019903 9.63 TP53 ERBB2 EGFR
5 protein binding GO:0005515 9.6 TP53 PRDX2 PPP3R1 PPIA PGR PDPN
6 steroid hormone receptor activity GO:0003707 9.5 PGR NR3C1 ESR1
7 nitric-oxide synthase regulator activity GO:0030235 9.43 ESR1 EGFR
8 nuclear receptor activity GO:0004879 9.33 PGR NR3C1 ESR1
9 steroid binding GO:0005496 9.13 PGR NR3C1 ESR1

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....